editor’s note: the only ones unsustainable are people and businesses like them… which they will soon become as they are forced to eat muck pie upon being crumbled by the soon to be released healing and free energy tech and the awesome businesses that will be forming to promote it. and besides ~ we are the value. who needs money in a truly free society. the old biz/corporate models are going bye-bye…
***
by Jay Syrmopoulos, April 24th, 2018
In a report entitled “The Genome Revolution” Goldman Sachs analyst Salveen Richter asked, “Is curing patients a sustainable business model?”
“The potential to deliver ‘one shot cures’ is one of the most attractive aspects of gene therapy, genetically-engineered cell therapy and gene editing. However, such treatments offer a very different outlook with regard to recurring revenue versus chronic therapies,” analyst Salveen Richter wrote in the note to clients on April 10. “While this proposition carries tremendous value for patients and society, it could represent a challenge for genome medicine developers looking for sustained cash flow.”
Richter highlighted the case of Gilead Sciences’ treatments for hepatitis C, which reportedly achieved cure rates of over 90 percent, as a cautionary tale.
“GILD is a case in point, where the success of its hepatitis C franchise has gradually exhausted the available pool of treatable patients,” the Goldman Sachs analyst wrote. “In the case of infectious diseases such as hepatitis C, curing existing patients also decreases the number of carriers able to transmit the virus to new patients, thus the incident pool also declines … Where an incident pool remains stable (eg, in cancer) the potential for a cure poses less risk to the sustainability of a franchise.”
Continue reading here.
